{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:08:44Z","timestamp":1784005724458,"version":"3.55.0"},"reference-count":29,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,5,1]]},"DOI":"10.1210\/jc.2006-2479","type":"journal-article","created":{"date-parts":[[2007,2,27]],"date-time":"2007-02-27T22:00:38Z","timestamp":1172613638000},"page":"1697-1704","source":"Crossref","is-referenced-by-count":103,"title":["Efficacy and Safety of Histrelin Subdermal Implant in Children with Central Precocious Puberty: A Multicenter Trial"],"prefix":"10.1210","volume":"92","author":[{"given":"Erica A.","family":"Eugster","sequence":"first","affiliation":[{"name":"Riley Hospital for Children (E.A.E.), Indiana University School of Medicine, Indianapolis, Indiana 46202"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Clarke","sequence":"additional","affiliation":[{"name":"University of Virginia (W.C.), Charlottesville, Virginia 22908"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad B.","family":"Kletter","sequence":"additional","affiliation":[{"name":"Seattle Childrens Hospital and Medical Center (G.B.K.), Seattle, Washington 98104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Lee","sequence":"additional","affiliation":[{"name":"Pennsylvania State Children\u2019s Hospital (P.A.L.), Hershey, Pennsylvania 17033"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Kirk","family":"Neely","sequence":"additional","affiliation":[{"name":"Stanford University Medical Center (E.K.N.), Stanford, California 94305"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward O.","family":"Reiter","sequence":"additional","affiliation":[{"name":"Baystate Children\u2019s Hospital (E.O.R.), Springfield, Massachusetts 01199"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Saenger","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center (P.S.), Bronx, New York 10461"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Shulman","sequence":"additional","affiliation":[{"name":"University of South Florida and All Children\u2019s Hospital (D.S.), St. Petersburg, Florida 33701"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Silverman","sequence":"additional","affiliation":[{"name":"Goryeb Children\u2019s Hospital Atlantic Health System (L.S.), Morristown, New Jersey 07962"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Flood","sequence":"additional","affiliation":[{"name":"Valera Pharmaceuticals (L.F., W.G., D.T.), Cranbury, New Jersey 08512"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gray","sequence":"additional","affiliation":[{"name":"Valera Pharmaceuticals (L.F., W.G., D.T.), Cranbury, New Jersey 08512"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tierney","sequence":"additional","affiliation":[{"name":"Valera Pharmaceuticals (L.F., W.G., D.T.), Cranbury, New Jersey 08512"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"issue":"Suppl 2","key":"key\n\t\t\t\t2019041114164331400_R1","first-page":"56","article-title":"Precocious puberty: growth and genetics","volume":"64","author":"Phillip","year":"2005","journal-title":"Horm Res"},{"key":"key\n\t\t\t\t2019041114164331400_R2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1515\/JPEM.2005.18.9.845","article-title":"Central precocious puberty in girls: prediction of the aetiology.","volume":"18","author":"Brauner","year":"2005","journal-title":"J Pediatr Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114164331400_R3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1210\/jcem-52-2-370","article-title":"Therapeutic use of pituitary desensitization with a long-acting LHRH agonist: a potential new treatment for idiopathic precocious puberty.","volume":"52","author":"Crowley Jr","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114164331400_R4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00019616-199106000-00005","article-title":"Central precocious puberty and its treatment with long-acting GnRH analogs.","volume":"1","author":"Hardin","year":"1991","journal-title":"Endocrinologist"},{"key":"key\n\t\t\t\t2019041114164331400_R5","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/00003081-199309000-00033","article-title":"Gonadotropin-releasing hormone agonists in the treatment of girls with central precocious puberty.","volume":"36","author":"Breyer","year":"1993","journal-title":"Clin Obstet Gynecol"},{"key":"key\n\t\t\t\t2019041114164331400_R6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/13543784.15.5.495","article-title":"Treatment of central precocious puberty.","volume":"15","author":"Tuvemo","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t2019041114164331400_R7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s004310051289","article-title":"Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues.","volume":"159","author":"Bertelloni","year":"2000","journal-title":"Eur J Pediatr"},{"key":"key\n\t\t\t\t2019041114164331400_R8","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1210\/jcem.86.10.7915","article-title":"Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience.","volume":"86","author":"Klein","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114164331400_R9","first-page":"653","article-title":"Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.","volume":"147","author":"Clemons","year":"1993","journal-title":"Am J Dis Child"},{"key":"key\n\t\t\t\t2019041114164331400_R10","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-3476(05)81074-1","article-title":"Preserving adult height potential in girls with idiopathic true precocious puberty.","volume":"117","author":"Kreiter","year":"1990","journal-title":"J Pediatr"},{"key":"key\n\t\t\t\t2019041114164331400_R11","first-page":"4583","volume":"84","author":"Heger","year":"1999"},{"key":"key\n\t\t\t\t2019041114164331400_R12","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1210\/jc.2001-020243","article-title":"Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg).","volume":"87","author":"Carel","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114164331400_R13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1530\/eje.1.02056","article-title":"Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.","volume":"154","author":"Carel","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041114164331400_R14","first-page":"292","article-title":"long-term suppression of pituitary-gonadal function with three-month depot of leuprorelin acetate in a girl with central precocious puberty.","volume":"58","author":"Schroeter","year":"2002","journal-title":"Horm Res"},{"key":"key\n\t\t\t\t2019041114164331400_R15","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1210\/jc.2005-1500","article-title":"Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty.","volume":"91","author":"Badaru","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114164331400_R16","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1056\/NEJM199905063401814","article-title":"A long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer","volume":"340","author":"Spitz","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114164331400_R17","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0090-4295(01)01293-6","article-title":"Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin.","volume":"58","author":"Schlegel","year":"2001","journal-title":"Urology"},{"key":"key\n\t\t\t\t2019041114164331400_R18","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0022-5347(05)67816-0","article-title":"An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.","volume":"163","author":"Chertin","year":"2000","journal-title":"J Urol"},{"key":"key\n\t\t\t\t2019041114164331400_R19","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1542\/peds.2005-0538","article-title":"The histrelin implant: a novel treatment for central precocious puberty","volume":"116","author":"Hirsch","year":"2005","journal-title":"Pediatrics"},{"key":"key\n\t\t\t\t2019041114164331400_R20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-3476(86)80767-3","article-title":"The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy.","volume":"108","author":"Pescovitz","year":"1986","journal-title":"J Pediatr"},{"key":"key\n\t\t\t\t2019041114164331400_R21","first-page":"30","article-title":"Use of leuprolide acetate response patterns in the early diagnosis of pubertal disorders: comparison with the gonadotropin-releasing hormone test.","volume":"78","author":"Ibanez","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114164331400_R22","first-page":"3408","article-title":"Acute hormonal responses to the gonadotropin releasing hormone agonist leuprolide: dose-response studies and comparison to nafarelin\u2014a clinical research center study.","volume":"81","author":"Rosenfield","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114164331400_R23","author":"Greulich","year":"1959"},{"key":"key\n\t\t\t\t2019041114164331400_R24","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/jcem-65-5-946","article-title":"Gonadotropin and \u03b1-subunit secretion during long term pituitary suppression by d-Trp6-luteinizing hormone-releasing hormone microcapsules as treatment of precocious puberty.","volume":"65","author":"Lahlou","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114164331400_R25","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/13543784.14.9.1085","article-title":"New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists.","volume":"14","author":"Schultze-Mosgau","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t2019041114164331400_R26","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1517\/13543784.11.9.1253","article-title":"Therapeutic potential of GnRH antagonists in the treatment of precocious puberty.","volume":"11","author":"Roth","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t2019041114164331400_R27","first-page":"890","article-title":"Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists.","volume":"75","author":"Jay","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114164331400_R28","first-page":"1696","article-title":"Long-term GnRH-agonist treatment does not postpone central development of the GnRH pule generator in girls with idiopathic precocious puberty.","volume":"80","author":"Schroor","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114164331400_R29","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/01.ju.0000152330.63175.a5","article-title":"Reversibility of androgen deprivation therapy in patients with prostate cancer.","volume":"173","author":"Fridmans","year":"2005","journal-title":"J Urol"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/5\/1697\/9052444\/jcem1697.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T20:03:10Z","timestamp":1556136190000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/92\/5\/1697\/2598321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,1]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2006-2479","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,1]]}}}